Since 1987, 12 start-up companies have been formed around Sanford-Burnham technologies. Some of the recent emerging companies include:
Avatar Therapeutics’ focus is on iPS cell programming using RNAi in diagnostics, therapeutics and organ toxicity. The San Diego-based company was founded by Tariq Rana, Ph.D., Director of Sanford-Burnham’s RNA biology program and professor at the Sanford Children’s Health Research Center.
CendR was co-founded by former Sanford-Burnham CEO and president Erkki Ruoslahti, M.D., Ph.D., and focuses on the peptide iRGD for oncology applications. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third the dosage.
ChemReGen’s focus is on novel therapeutic and diagnostic reagents for cardiogenesis. The company is based in San Diego and was founded by Sanford-Burnham’s Mark Mercola, Ph.D., professor at Sanford Children’s Health Research Center and director of the Muscle Development and Regeneration Program. Read more.
Vala Sciences Inc.
Vala Sciences is a San Diego-based biotechnology company serving academic, pharmaceutical and biotechnology scientists. Vala’s hardware, CyteSeer automated cell image analysis software and reagents, enable information-rich measurements for making fundamentally new insights into the cell functions critical to progress in the biological sciences. Jeffrey H. Price, M.D., Ph.D., is founder, president and chief executive officer of Vala and associate professor at Sanford-Burnham’s NCI-designated cancer center. Read more.